[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fondazione Epatocentro Ticino\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":142},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,63,95,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100297045","swiss-autoimmune-hepatitis-cohort-study-100297045",false,"NCT03146884","Swiss Autoimmune Hepatitis Cohort Study","Inclusion Criteria:\n\n* diagnosis of AIH, either type I or type II\n* Only patients living in Switzerland\n\nExclusion Criteria:\n\n* N\u002FA",true,"ALL",{"count":18,"type":19},500,"ESTIMATED","5 Years","OBSERVATIONAL","Research project in which biological material is sampled and health-related personal data is further used and collected.\n\nCoded data are used.",[24,25],"Hepatitis, Autoimmune","Autoimmune Hepatitis",[25,27,28],"AIH","Cohort","RECRUITING","2025-08-14",{"date":32,"type":33},"2025-08-18","ACTUAL",{"date":35,"type":33},"2017-02-16",{"date":37,"type":19},"2030-12-31",{"name":39,"class":40},"Fondazione Epatocentro Ticino","OTHER",20,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":50,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":62},"100297049","swiss-primary-sclerosing-cholangitis-cohort-study-100297049","NCT03146936","Swiss Primary Sclerosing Cholangitis Cohort Study","Inclusion Criteria:\n\n* Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases) of any age. Patients not fulfilling such criteria but still diagnosed with PSC in a hepatology referral centre can be included\n* patients living in Switzerland\n\nExclusion Criteria:\n\n* N\u002FA",{"count":49,"type":19},120,[51,52,53],"Cholangitis, Sclerosing","PSC","Primary Sclerosing Cholangitis (PSC)",[52,55,28],"Primary Sclerosing Cholangitis",{"date":57,"type":33},"2025-08-19",{"date":59,"type":33},"2017-02-28",{"date":37,"type":19},{"name":39,"class":40},21,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100584261","phase-2-methylene-blue-treatment-of-chronic-hepatitis-b-virus-infection-100584261","NCT06887036","Methylene Blue Treatment of Chronic Hepatitis B Virus Infection","Methylene Blue Treatment of Chronic Hepatitis B Virus Infection: a Pilot Study","MB_HBV","Inclusion Criteria:\n\n* Signed informed consent\n* Age ≥ 18 and \\\u003C 80 years\n* Microbiologically confirmed chronic Hepatitis B Virus infection (according to the old terminology \"inactive HBV carrier\")\n* HBsAg levels within 20-15'000 IU\u002Fml measured at the at least twice at 6-18 months apart\n* HBV DNA PCR levels within 1'000-20'000 IU\u002Fml measured at least twice at 6-18 months apart\n* Negative pregnancy test in women of child-bearing age\n\nExclusion Criteria:\n\n* Documented refusal to participate in the study\n* Known G-6-Phophatase deficiency\n* Treatment with a serotoninergic drug\n* Ongoing treatment with a nucleos(-t)ide treatment\n* Clinically relevant concomitant liver disease\n* GPT \\> 2xULN\n* Fibroscan of \\> 8.0 KPa obtained ≤ 12 months before Visit 0\u002FScreening\n* HBeAg positivity\n* Anti HDV antibody positivity\n* Breastfeeding women","18 Years","79 Years",{"count":74,"type":19},10,"INTERVENTIONAL",[77],"PHASE2","HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV carriers worldwide, of whom approximately 600,000 die each year from HBV-related liver disease. Diagnosis and treatment depend on the stage of infection, the degree of liver inflammation, and the progression of fibrosis. Patients with HBeAg-positive or -negative hepatitis are usually treated with nucleos(-t)ide analogues. This treatment inhibits HBV reverse transcriptase and reduces viral replication, but does not affect HBsAg production. Treatment must be continued for life in most cases and is associated with high cumulative costs and the risk of development of resistance.\n\nRecently, it has been shown that patients who show a decrease in their HBsAg levels are more likely to become HBsAg negative, seroconvert and be able to stop antiviral treatment, which is the ultimate goal of treatment, but unfortunately rarely achieved. Methylene blue (MB) has been shown to have an effect on HBsAg levels in vitro, making it a promising test for a new treatment for HBV.\n\nThis is an explorative pilot study, open label, dose-escalation, single center clinical trial on the efficacy of MB against HBV infection.\n\nPrimary objective is to assess the efficacy of incremental doses of MB against hepatitis B virus in patients with chronic hepatitis B assessed by the reduction of both the HBsAg and HBV DNA levels after 6 months of treatment and 6 months of follow-up.\n\nParticipant will be treated for 6 months with MB 100 mg capsules, and then followed up for a further 6 months. The initial dose of MB might be increased if the patient is a non-responder.",[80],"Chronic HBV Infection",[82,83,84,85],"HBV","chronic HBV","Methylene Blue","MB","2025-08-13",{"date":88,"type":33},"2025-08-17",{"date":90,"type":19},"2025-09",{"date":92,"type":19},"2026-10-31",{"name":39,"class":40},1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":101,"targetDuration":102,"studyType":21,"phases":4,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":113,"locationsCount":114},"100297047","swiss-primary-biliary-cholangitis-cohort-study-100297047","NCT03146910","Swiss Primary Biliary Cholangitis Cohort Study","Inclusion Criteria:\n\n* diagnose of Primary biliary cholangitis (according to EASL Clinical Practice Guidelines: management of cholestatic liver diseases).\n* Subjects with isolated anti-mitochondrial antibodies and\u002For isolated PBC-specific anti-nuclear antibodies are also included\n* Patients\u002Fsubjects aged at least 18 years and living in Switzerland are included\n\nExclusion Criteria:\n\n* N\u002FA",{"count":18,"type":19},"10 Years","Research project in which biological material is sampled and health-related medical data is collected. In addition, already existing health-related medical data are used for further research. Coded data are used.",[105,106],"PBC","Primary Biliary Cholangitis",[105,106,28,108],"AILD",{"date":88,"type":33},{"date":111,"type":33},"2017-02-15",{"date":37,"type":19},{"name":39,"class":40},13,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":21,"phases":4,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":94},"100596929","prospective-cohort-and-biobank-of-patients-with-nonalcoholic-fatty-liver-disease-100596929","NCT07051863","Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease","Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease (NAFLD Cohort Study)","NAFLD Cohort","Inclusion Criteria:\n\n1. Participant must be ≥ 18 years of age at the time of signing the informed consent\n2. Participant willing to sign the informed consent form (ICF) and to complete all study-specific procedures and visits\n3. To have a diagnosis of NAFLD\u002FNASH\u002FMAFLD followed at Epatocentro Ticino and collaborating\u002Freferring clinicians based on:\n\n   1. Liver biopsy with a histological evidence of NAFLD\u002FNASH\u002FMAFLD OR\n   2. Liver imaging (ultrasound, CT scan, MRI, CAP Controlled Attenuation Parameter) OR\n   3. Diagnosis of metabolic syndrome and liver fibrosis or cirrhosis without an alternative diagnosis; metabolic syndrome fulfilling one or more of the below mentioned conditions:\n\n      * Abdominal obesity: a waist circumference of more than 35 inches (\\>89cm) for women and more than 40 inches (\\>102 cm) for men;\n      * High blood pressure of 130\u002F80 mm Hg or higher. Normal blood pressure is defined as less than 130 mm Hg for systolic pressure, and less than 80 mm Hg for diastolic pressure\n      * Impaired fasting blood glucose. This means a level equal to or greater than 100 mg\u002FdL (\\>5.6 mmol\u002FL)\n      * High triglyceride levels of more than 150 mg\u002FdL (\\> 1.7mmol\u002FL).\n      * Low HDL (good) cholesterol: less than 40 mg\u002FdL (\\\u003C 1.04 mmol\u002FL) for men and less than 50 mg\u002FdL (\\\u003C 1.29 mmol\u002FL) for women\n4. alcohol consumption less than 21 (males) or 14 (women) units per week in the 6 months before the enrolment and no history of excessive alcohol consumption in the 5 years before enrolment. One unit is 12g (grams) of pure alcohol; 10-12 grams of pure alcohol are contained in a 280-330 ml of beer, 150-180 ml of champagne, 30-40 ml of whisky or high-strength spirit, 60-80 ml of liqueur, and 100-120 ml of red wine\n\nExclusion Criteria:\n\n1. To have a diagnosis of type I diabetes mellitus\n2. To have a concomitant liver disease\n3. To take or have taken in the last 12 months before enrolment, on more than 50% of days, drugs that may cause liver steatosis (long-term high dose systemic corticosteroids (\\> 20mg prednisone equivalent), amiodarone, methotrexate, tamoxifen, tetracycline, high dose estrogens and valproic acid)\n4. Pregnancy and breast feeding.",{"count":124,"type":19},200,"6 Months","The goal of this observational study is to establish a unified cohort for retrospective and prospective high quality baseline and follow-up data registration of patients with a diagnosis of NAFLD\u002FNASH\u002FMAFLD, according to standardized criteria.\n\nThis will allow future studies aimed at elucidate clinical presentation, natural history, response to treatment, genetic and metabolic risk factors, treatment options and outcomes of the disease. The cohort will allow investigators to carry out genetic, serological, microbiologic and immunological studies.",[128,129,130],"NAFLD","MASH","NASH\u002FMASH",[128,129,132,133],"NASH","Steatoepatitis","2025-07-04",{"date":136,"type":33},"2025-07-09",{"date":138,"type":33},"2023-07-19",{"date":140,"type":19},"2030-12",{"name":39,"class":40},""]